Author

Mera K. Tilley

Observed names: M.K. Tilley, Mera Tilley, Tilley, Mera, Tilley, Mera K

Institution: Alumis Inc. (United States)

Observed institutions: National Institutes of Health, Pennsylvania State University, Johns Hopkins University, Pfizer (United States), Johns Hopkins Medicine, National Human Genome Research Institute, Alumis Inc. (United States), University of Colorado Anschutz, University of Colorado Denver

OpenAlex ID: A5059050309

A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes

2018 · Natalie R. van Zuydam, Emma Ahlqvist, et al. · Diabetes · 195

The Interleukin‐1 Receptor–Associated Kinase 4 Inhibitor PF‐06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial

2021 · Aaron Winkler, Weiyong Sun, et al. · Arthritis & Rheumatology · 90

GWAS of self-reported mosquito bite size, itch intensity and attractiveness to mosquitoes implicates immune-related predisposition loci

2017 · Amy V. Jones, Mera Tilley, et al. · Human Molecular Genetics · 36

CHD7 Gene Polymorphisms and Familial Idiopathic Scoliosis

2013 · Mera K. Tilley, Cristina M. Justice, et al. · Spine · 15

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral allosteric TYK2 inhibitor ESK‐001 using a randomized, double‐blind, placebo‐controlled study design

2024 · Sibel Ucpinar, Joyce K. Kwan, et al. · Clinical and Translational Science · 12

Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging phase 2 study

2025 · Andrew Blauvelt, Petr Arenberger, et al. · Journal of the American Academy of Dermatology · 10

Distinct clinical phenotypes for Crohn’s disease derived from patient surveys

2021 · Tianyun Liu, Lichy Han, et al. · BMC Gastroenterology · 9

Envudeucitinib, a Potent, Next-Generation, Allosteric Inhibitor of TYK2: A Narrative Review

2026 · April W. Armstrong, James G. Krueger, et al. · Dermatology and Therapy · 1

A Chromosome 13 locus is associated with male-specific mortality in mice

2015 · Joseph P. Gyekis, Dean H. Lang, et al. · Aging Clinical and Experimental Research · 1

0111 Envudeucitinib, an allosteric TYK2 inhibitor, inhibits TYK2-relevant biomarkers in skin using spatial transcriptomics

2026 · N. Narayan, J. Hoffman, et al. · Journal of Investigative Dermatology

73714 Envudeucitinib Attenuates Inflammatory Biomarkers in Plaque Psoriasis at Both a Proteomic and Transcriptomic Level: A Subgroup Analysis of Tape Strip Biomarkers from the STRIDE Phase 2 Clinical Trial

2026 · Mera Tilley, Joshua Hoffman, et al. · Journal of the American Academy of Dermatology

257 Transcriptomic and Proteomic Modulation in Psoriatic Skin Following Envudeucitinib Treatment: Subgroup Analysis of a Phase 2 Randomized Trial

2025 · Jerry Zhou, Jacob Fiedler, et al. · Journal of Investigative Dermatology

62905 ESK-001, an allosteric TYK2 inhibitor, modulates disease and TYK2-related pathway transcriptomic and proteomic biomarkers in Psoriasis STRIDE trial patients

2025 · Nicole Narayan, Josh Hoffman, et al. · Journal of the American Academy of Dermatology

0476 Maximal and sustained TYK2 inhibition: The key to higher efficacy with oral allosteric inhibitors

2025 · S. Ucpinar, J.K. Kwan, et al. · Journal of Investigative Dermatology

0116 ESK-001, an allosteric TYK2 inhibitor, inhibits TYK2-and psoriasis-relevant biomarkers in skin using spatial transcriptomics

2025 · N. Narayan, J.D. Hoffman, et al. · Journal of Investigative Dermatology

Works count: 18

Citation count: 370

H-index: 7

I10-index: 6